BioIVT

If you missed any of our presentations at the #ISSX2026 North American Meeting this week, you can now access everything here: 𝗣𝗼𝘀𝘁𝗲𝗿 𝗣𝟳𝟵 “Development of a #Bioinformatics-Guided Pan-UGT1A #siRNA for Low-Turnover Compound Reaction Phenotyping in HEPATOPAC” ➡️ https://hubs.ly/Q04Bj6-R0 𝗣𝗼𝘀𝘁𝗲𝗿 𝗣𝟱𝟴 “Establishing the Translational Relevance of Modeling #MASLD in HEPATOPAC Through Proteomic Profiling” ➡️ https://hubs.ly/Q04Bj7N90 𝗣𝗼𝘀𝘁𝗲𝗿 𝗣𝟭𝟮𝟲 “Characterization of Lipid-Modified Peptide #GLP1 Receptor Agonist Metabolism in Sandwich-Cultured #Hepatocytes Using Extended In Vitro Incubations” ➡️ https://hubs.ly/Q04Bj6ZT0 𝗕𝗿𝗲𝗮𝗸𝗳𝗮𝘀𝘁 𝗦𝘆𝗺𝗽𝗼𝘀𝗶𝘂𝗺 “Advancing In Vitro Approaches to Explore Tissue Metabolism of Complex #PeptideTherapeutics: A GLP-1 Case Study” ➡️ https://hubs.ly/Q04Bj7P50 𝗧𝗵𝗼𝘂𝗴𝗵𝘁 𝗟𝗲𝗮𝗱𝗲𝗿 𝗣𝗿𝗲𝘀𝗲𝗻𝘁𝗮𝘁𝗶𝗼𝗻 “Transporting Across the #BloodBrainBarrier” ➡️ https://hubs.ly/Q04Bj6ZV0 A big thank you to Joanna Barbara, Mark Warren, Christian Smith, Karissa Cottier, and Seema Muranjan for sharing your expertise and insights. And of course, just let us know if you’d like to discuss any of these materials with our experts! #ADME #DMPK #DrugMetabolism #DrugInteractions

Organ and tissue donation isn’t just critical for transplantation. It is a powerful catalyst for scientific discovery and innovation. In this webinar hosted by the Col·legi de Biòlegs de Catalunya, Dir. of Technical Operations at BeCytes Biotechnologies, A BioIVT Company, Estephan Arredondo, will discuss how biologists transform donated tissues into high-quality resources that support advanced preclinical and translational studies, including best practices in tissue procurement, processing, and traceability. 📅 October 21, 2026 ⏰ 17:00 CET | 11:00 AM ET 𝗧𝗵𝗲 𝗽𝗿𝗲𝘀𝗲𝗻𝘁𝗮𝘁𝗶𝗼𝗻 𝘄𝗶𝗹𝗹 𝗯𝗲 𝗶𝗻 𝗦𝗽𝗮𝗻𝗶𝘀𝗵. Learn more and register: https://lnkd.in/ecxu2-kG #OrganDonation #BiomedicalResearch #LifeSciences #ResearchModels

What happens when your study requires highly specific donor samples and hundreds of millions of #PBMCs per donor? An #immunology research team recently ran into this exact challenge. They needed disease-specific donor samples capable of generating at least 400 million PBMCs per donor, along with HLA typing and viral testing. Traditional clinical collection sites simply couldn’t provide disease-specific samples at the scale needed. To overcome this hurdle, the research team partnered with BioIVT to develop a prospective donor-center collection strategy tailored to the team’s assay requirements. Together, we were able to screen existing participants and recruit new, qualified #MultipleSclerosis donors. Ultimately, the team was able to secure the right biological materials at the volume their research demanded. And, because the donors were recallable, researchers could return to the same population for follow-up, ensuring the team wouldn’t need to repeatedly qualify new donors. When the right samples are difficult to find, BioIVT works as an extension of your research team to help identify the right #donor source, collection approach, and biological materials for your study. Read the full case study below, and explore solutions tailored to your immunology research program here: https://hubs.ly/Q04zTJf60

Earlier this year, our presentation on pre-analytical considerations in #LiquidBiopsy generated significant interest and plenty of great questions. We’ve taken your interest a step further, bringing together the insights, questions, and extensive resources behind the presentation into a valuable eBook titled "A Practical Guide to Achieving Trial-Ready Liquid Biopsy”. Researchers can now take a deeper look at the variables that can influence sample quality and downstream results, including analyte stability, collection tube chemistry, biospecimen handling, workflow considerations, and quality control. Explore all seven chapters in the full 44-page guide: https://hubs.ly/Q04zTG5-0 Watch the original presentation: https://hubs.ly/Q04zTGLc0

Looking for the latest from BioIVT scientists and collaborators?   Here’s a snapshot of recent updates, featuring publications and presentations on topics including #immunology, #ADME, #liquidbiopsy, #NAMS and #toxicity from experts including Courtney Noah, Joanna Barbara, Marc Terrones, Estephan Arredondo, Tina Mueller, Kenneth Brouwer, and Mark Warren:   ➡️ 5 Common Assumptions That Can Limit Translational Immunology Research ➡️ A Practical Guide to Achieving Trial-Ready Liquid Biopsy ➡️ In Vitro Lysosomal Catabolism of GLP-1 Peptide Therapeutics: A Human vs Rat Species Comparison ➡️ Alveolar Cells in Preclinical Lung Models: Why Mixed Cell Populations Improve Biological Relevance ➡️ 3D Bioprinted Liver models for Preclinical Research ➡️ Mechanism-Based Human In Vitro Screen for Prediction of Cholestatic Liver Toxicity ➡️ And more! Catch up on the latest science, resources, and expert perspectives from BioIVT and subscribe to receive future updates directly in your inbox ⬇️

𝗕𝗲𝗮𝘁 𝘁𝗵𝗲 𝘆𝗲𝗮𝗿-𝗲𝗻𝗱 𝗿𝘂𝘀𝗵. We’ve built strong inventory across high-demand disease-state biospecimens to support research needs now and into 2027. But as Q4 progresses and year-end ordering ramps up, availability can change quickly. If you know what you’ll need, now is the time to secure it. Current areas of strong availability include: • Disease- and normal-state CSF • Serum, plasma, and other blood-derived biofluids • Ethically sourced clinical tissues Don’t wait until year-end demand picks up to start looking for the biospecimens your research needs. Buy now while inventory is strong. Be ready for what’s next. https://hubs.ly/Q04zTwx50

Attending the #ISSX2026 North American Meeting? Stop by booth #504 to discuss your ADME/DDI study, test system or consulting questions and needs with our expert team, including Brian Ogilvie, Kent Grindstaff, Kenneth Brouwer, Jackie Bowlin, Chris Bohl, Ana Vergara, Garret Morton, Basile Siewe, Noemi Rosario, Qiming Wang, and more! And make sure to catch: 𝟳:𝟭𝟱𝗮𝗺 𝗧𝘂𝗲𝘀, 𝗢𝗰𝘁. 𝟭𝟯 𝗶𝗻 𝘁𝗵𝗲 𝗣𝗹𝗮𝘇𝗮 𝗺𝗲𝗲𝘁𝗶𝗻𝗴 𝘀𝗽𝗮𝗰𝗲 Joanna Barbara will be providing a breakfast symposium presentation on “Advancing In Vitro Approaches to Explore Tissue Metabolism of Complex #PeptideTherapeutics: A GLP-1 Case Study” 𝟭𝟮:𝟯𝟬𝗽𝗺 𝗧𝘂𝗲𝘀, 𝗢𝗰𝘁. 𝟭𝟯 𝗶𝗻 𝘁𝗵𝗲 𝗘𝘅𝗵𝗶𝗯𝗶𝘁 𝗛𝗮𝗹𝗹 Mark Warren will be providing a Thought Leader Presentation on “Transporting Across the #BloodBrainBarrier” 𝟭𝟮:𝟬𝟬-𝟭𝟮:𝟰𝟱𝗽𝗺 𝗧𝘂𝗲𝘀, 𝗢𝗰𝘁. 𝟭𝟯 𝗣𝗼𝘀𝘁𝗲𝗿 𝗣𝟳𝟵 Christian Smith will present “Development of a #Bioinformatics-Guided Pan-UGT1A #siRNA for Low-Turnover Compound Reaction Phenotyping in HEPATOPAC” 𝟭𝟮:𝟰𝟱-𝟭:𝟯𝟬𝗽𝗺 𝗧𝘂𝗲𝘀, 𝗢𝗰𝘁. 𝟭𝟯 𝗣𝗼𝘀𝘁𝗲𝗿 𝗣𝟱𝟴 Karissa Cottier, PhD will present “Establishing the Translational Relevance of Modeling #MASLD in HEPATOPAC Through Proteomic Profiling” 𝟭𝟮:𝟰𝟱-𝟭:𝟯𝟬𝗽𝗺 𝗪𝗲𝗱, 𝗢𝗰𝘁. 𝟭𝟰 𝗣𝗼𝘀𝘁𝗲𝗿 𝗣𝟭𝟮𝟲 Seema Muranjan will present “Characterization of Lipid-Modified Peptide #GLP1 Receptor Agonist Metabolism in Sandwich-Cultured #Hepatocytes Using Extended In Vitro Incubations” See you there! #ADME #DMPK #DrugMetabolism #DrugInteractions

At BioIVT, our mission centers on advancing scientific discovery, powered by individuals who support research through our donor programs. Across areas like autoimmune disease and cancer diagnostics, donor participation plays a vital role in driving progress. Learn more ⬇️ US: https://hubs.ly/Q04z8QtW0 UK: https://hubs.ly/Q04z8QXz0

Did you miss our poster from the DMDG-GMP-SPS Joint Meeting? It’s now available to download from our website! Joanna Barbara, PhD, General Manager for BioIVT's ADME Services, presented "In Vitro Lysosomal Catabolism of GLP-1 Peptide Therapeutics: A Human vs. Rat Species Comparison." Peptide drugs metabolized by numerous tissues and compartments require appropriate in vitro tools. Two GLP-1 agonists were profiled in human liver lysosomes and rat liver tritosomes for in vitro metabolism species comparison potential. Tritosomes are derived from animals dosed with tyloxopol, which accumulates in lysosomes, improving separation from mitochondria for enhanced purity. View the poster now: https://hubs.ly/Q04zmt4f0 #ADME #GLP1 #PeptideTherapeutics #DrugMetabolism

#ProteinDegraders, including #PROTACs, bring unique challenges to in vitro #ADME assessment, requiring workflows that account for their complex properties. At the 9th TPD & Induced Proximity Summit, BioIVT Scientific Advisor, Tina Mueller, PhD will present “The In Vitro ADME Playbook for Protein Degraders: What’s Different?” On Tuesday, October 27 at 1:30 pm, Tina will be covering workflow adaptations for heterobifunctional protein degraders, a case study featuring the in vitro characterization of ARV-825 and JNJ-1013, and considerations for generating actionable ADME and safety data to support discovery and development. And be sure to connect with Kevin Mertz to setup a meeting or stop by the BioIVT table to discuss your test system sourcing or study needs: https://hubs.ly/Q04z8NwK0